Drug intelligence / Profile preview

D308

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D308 is an investigational pharmaceutical drug developed by Chong Kun Dang Pharmaceutical. It has been evaluated in Phase 1 clinical trials to assess drug-drug interactions with CKD-501 and to compare its pharmacokinetic characteristics and safety with CKD-380 (Dapagliflozin) in healthy male adults. Its specific mechanism of action and primary indication are not disclosed in the provided context.

Beyond the preview

Go deeper on D308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D308.

Explore the full profile